FDA批准标签变更，包括使用西他卡布根Autoleucel治疗后免疫效应细胞相关性小肠结肠炎的方框警告; CARVYKTI的确定总体获益继续超过批准使用的潜在风险

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-labeling-changes-include-boxed-warning-immune-effector-cell-associated-enterocolitis